Immunex Corporation

Amgen Inc.

Just-evotec Biologics, Inc.

Just-evotec Biologies, Inc.

Jeffrey T McGrew

E-Ching Ong

Pauline S Smidt

Richard Jeffrey Armitage

William Christian Fanslow, Iii

Melanie K Spriggs

Arvia Eleanor Morris

Subhashini Srinivasan

Marylou G Gibson

John Ernest Sims

Dirk E Smith

Marek Z Kubin

Kirk P Van Ness

Louise Conroy

Michael T Trentalange

Allison Adin Bianchi

Thomas J Graddis

Bradley D Dell

Randal Robert Ketchem

Duncan James Cochrane

Dina A Fomina Yadlin

Duncan Cochrane

Kristine M Daris

Trent P Munro

Allison A Bianchi

Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5' PiggyBac ITR and a 3&#x2032; PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.

Expression from transposon-based vectors and uses

Inducible expression from transposon-based vectors and uses

This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.

Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors

A hybrid promoter for recombinant expression of proteins of interest is disclosed that combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Also disclosed are an expression cassette containing the hybrid promoter and a recombinant expression vector containing the expression cassette. A mammalian host cell, which comprises the recombinant expression vector is also disclosed, as is a method of producing a protein of interest that employs the mammalian host cell, optionally involving tetracycline-inducible expression of the protein.

Hybrid promoter and uses thereof

Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.

Methods of treatment using IL-18 receptor antigen binding proteins

IL-18 receptor antigen binding proteins

This invention is in the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.

Selection of cells expressing heteromeric polypeptides

This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.

The invention provides methods of increasing the production of polypeptides, optionally recombinant polypeptides, from mammalian cells using xanthine derivatives or hybrid polar compounds and cultures containing the same. Combinations of inducers including a hybrid polar compound and/or a xanthine derivative and/or an alkanoic acid can also be used, optionally at temperatures less than 37&#xb0; C.

Methods for increasing polypeptide production

A screening method for identifying mutant polypeptides having at least one amino acid difference from a wild type protein involved in a receptor-ligand interaction is disclosed. Also disclosed are mutant polypeptides of the hematopoietic growth factor flt3-Ligand (flt3-L) identified using this method, nucleic acids encoding these flt3-L mutant polypeptides, and methods of treatment involving in vitro and in vivo use of the mutant polypeptides and nucleic acids.

Methods of using mutant flt3-ligand polypeptides to induce cellular expansion

The invention provides methods and compositions for improved in vitro culture of cells that make use of vanadate. The methods enhance cell survival thereby recovery of the polypeptide of interest produced in the cells is increased relative to cells grown without vanadate.

Cell culture performance with vanadate

There is disclosed an expression vector utilizing an internal polyadenylation signal. The internal polyadenylation signal is inserted between a DNA encoding a protein of interest and a DNA encoding a selectable marker, and allows a single promoter to generate both monocistronic messages and dicistronic messages. Similar, multicistronic vectors can also be prepared. Also disclosed are methods of using the expression vector utilizing an internal polyadenylation signal, host cells transfected therewith, stable pools of cells transfected with an expression vector utilizing an internal polyadenylation signal, and clones of such transfected cells.

Vectors and methods for recombinant protein expression

Growing community of inventors

Seattle, WA, United States of America

Jeffrey T McGrew